BMS 824393Alternative Names: BMS-824393
Latest Information Update: 28 Aug 2015
At a glance
- Originator Bristol-Myers Squibb
- Class Antivirals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 11 Aug 2010 Phase-II clinical trials in Hepatitis C (in combination with peginterferon alfa-2a and ribavirin, in treatment naive patients) in USA (PO)